FindTrial
Sign In

Effects of selenium and vitamin D supplementation on autoimmune thyroiditis in women of reproductive age

Research and Translation of the Lingnan Dietary Pattern

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119403
Enrollment
Unknown
Registered
2026-02-26
Start date
2025-10-17
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Thyroiditis

Interventions

Selenium and Vitamin D Combination Supplementation Group:Selenium supplements (200 µg/day) and vitamin D supplements (800 IU/day) for 3 months
Selenium Supplementation Group:Selenium supplements (200 µg/day) and vitamin D placebo for 3 months
Control Group:Selenium placebo and vitamin D placebo for 3 months
Observational study group:None

Sponsors

Guangdong Provincial Center for Disease Control and Prevention
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 49 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for the observational study phase: Adults who underwent health check-ups at Guangzhou Panyu Health Management Center. Inclusion criteria for the intervention study phase: 1. Women aged 18-49; 2. Serum TPOAb > 34IU/ml and/or serum TgAb > 115IU/ml; 3. TSH, FT3, and FT4 levels are normal.

Exclusion criteria

Exclusion criteria: Exclusion criteria for the observational study phase: 1. Pregnant or lactating women. 2. History of thyroid tumor, thyroid surgery, or prior use of medications for thyroid disorders or treatment with radioiodine (I¹³¹). 3. Patients with other tumors, severe cardiovascular diseases or other serious conditions. Exclusion criteria for the intervention study phase: 1. Pregnancy, lactation, or planning to become pregnant within the next three months. 2. History of thyroid tumor, thyroid surgery, or prior use of medications for thyroid disorders or treatment with radioiodine (I¹³¹). 3. Coexisting autoimmune diseases requiring the use of immunomodulatory agents. 4. Patients with severe gastrointestinal disorders that may affect drug absorption, distribution, or elimination (e.g., severe peptic ulcer, vomiting, diarrhea, delayed gastric emptying, intestinal obstruction). 5. Patients with previously diagnosed hepatic or renal dysfunction.

Design outcomes

Primary

MeasureTime frame
Thyroid Peroxidase Antibodies (TPOAb);Thyroglobulin Antibodies (TgAb);Plasma selenium;Plasma vitamin D;—

Secondary

MeasureTime frame
Thyroid-stimulating hormone (TSH);Free triiodothyronine (FT3);Free thyroxine (FT4);Urine iodine;—

Countries

China

Contacts

Public ContactGangqiang Ding

Guangdong Provincial Center for Disease Control and Prevention

dinggq@chinacdc.cn+86 10 6623 7001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026